Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (2,879) $ (8,390)
Loss (income) from discontinuing operations (74) 6,199
Loss from continuing operations (2,953) (2,191)
Adjustments to reconcile net loss to net cash used in operating activities, continuing operations:    
Depreciation 90 36
Amortization 214 223
Stock-based compensation 113 186
Change in fair value of warrant liability, acquisition note payable and other derivatives (156) (292)
Amortization of operating lease right-of-use assets 76 85
Change in fair value of siParadigm Earn-Out 65 0
Amortization of discount on debt and debt issuance costs 63 470
Loss on extinguishment of debt 31 256
Interest added to Convertible Note 0 268
Changes in:    
Accounts receivable 82 86
Other current assets 136 3
Other non-current assets (5) 55
Accounts payable, accrued expenses and deferred revenue 321 889
Due to Interpace Biosciences, Inc. 628 0
Obligations under operating leases (125) (107)
Net cash used in operating activities, continuing operations (1,420) (33)
Net cash used in operating activities, discontinuing operations (481) (4,827)
Net cash used in operating activities (1,901) (4,860)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of fixed assets (39) (21)
Distribution from Joint Venture 36 0
Receipts from Excess Consideration Note 888 0
Net cash provided by (used in) investing activities, continuing operations 885 (21)
Net cash provided by (used in) investing activities, discontinuing operations 40 (34)
Net cash provided by (used in) investing activities 925 (55)
CASH FLOWS FROM FINANCING ACTIVITIES    
Principal payments on obligations under finance leases (23) (25)
Proceeds from offerings of common stock, net of certain offering costs 0 5,412
Payments on Advance from NovellusDx, Ltd. (300) 0
Net cash provided by (used in) financing activities, continuing operations (323) 5,387
Net cash provided by financing activities, discontinuing operations 0 75
Net cash provided by (used in) financing activities (323) 5,462
Effect of foreign exchange rates on cash and cash equivalents and restricted cash (67) (41)
Net increase (decrease) in cash and cash equivalents and restricted cash (1,366) 506
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH    
Beginning 4,230 511
Ending 2,864 1,017
RECONCILIATION OF CASH AND CASH EQUIVALENTS AND RESTRICTED    
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH 2,864 1,017
SUPPLEMENTAL CASH FLOW DISCLOSURE    
Cash paid for interest 7 694
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES    
Common stock issued in VentureEast settlement 12 0
Fair value of common stock exchanged to settle Note Payable 531 0
Right of use assets obtained through operating leases 27 0
Fixed assets obtained through finance leases 17 145
Conversion of debt and accrued interest into common stock $ 0 $ 350